ALKERMES PUBLIC LIMITED COMPANY
ALKS · NASDAQ
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
Market Data
Price
$52.85
+1.13 (+2.18%)
Market Cap$8.56B
P/E Ratio56.08
EPS$—
52W High$55.67
52W Low$25.17
Beta0.26
Data from Finnhub · Updated Jul 22, 2026